Sodium nitrite oral - Theravasc

Drug Profile

Sodium nitrite oral - Theravasc

Alternative Names: TV-1001; TV1001SR

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TheraVasc
  • Developer Soin Neuroscience; TheraVasc; University of Colorado at Boulder
  • Class Antidotes; Antihypertensives; Nitrites; Small molecules; Sodium compounds; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic angiopathies; Diabetic neuropathies
  • Phase I/II Vascular disorders
  • Preclinical Systemic scleroderma

Most Recent Events

  • 10 Aug 2017 Sodium nitrite oral licensed to Cleveland Diabetes Care worldwide for Diabetic neuropathic pain
  • 10 Aug 2017 Soin files for patent protection for sodium nitrite oral
  • 10 Aug 2017 Soin Neuroscience announces intention to submit NDA to USFDA for Diabetic neuropathic pain and Systemic sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top